IL-17

Interleukin 17 (IL-17) is a strong inducer of inflammation and it helps in our protection against invading pathogens. It can also have however a detrimental role, as in chronic inflammatory and autoimmune diseases, IL-17 contributes in tissue destruction.

Client:

Qode Interactive

Date:

January 21, 2024

Category:

IL17A as a therapeutic target

Due to its central role in orchestrating the pathogenesis of multiple inflammatory conditions, including rheumatoid arthritis, psoriasis, IBD, multiple sclerosis (MS) and others, IL-17 is a promising therapeutic target. Indeed several approaches that target IL-17 signaling have been tested in the clinic with real benefits to the patients and biologics that target IL-17, such as secukinumab (Cosentyx) and Ixekizumab (Taltz), have been now clinically approved for indications including psoriasis and psoriatic arthritis.

Preclinical Platforms for the evaluation of IL17 targeting therapeutics

d
TghIL17

TghIL17 mice express human IL-17 in the absence of mouse IL-17.

d
IMQ psoriasis in TghIL17

IMQ induced psoriasis pathology model in TghIL17 mice offer a unique tool for the evaluation of anti-hIL17 therapeutics .

d
MOG-EAE in TghIL17

MOG induced EAE in hTNFR1KI mice offer a unique tool for the evaluation of anti-hIL17 therapeutics .

Enhance Your Research Strategy Today

Partner with Our Skilled Scientists and discover Cutting-Edge Solutions!
Contact Us